Medical Ethics — Four Principles and the Three at the Bedside— Autonomy, non-maleficence, beneficence, justice — read in the language of clinical practice, not the textbook

01Why "medical ethics" needs its own territory

Three reasons set medical ethics apart from ethics in general. One — it deals with life and health. Mistakes have irreversible consequences, so the principles have to be stricter. Two — asymmetry of knowledge and capacity. The patient is not a medical specialist; the clinician is. This gap rules out contractual symmetry. Three — the strong drive to heal, to save. Good intentions run hot here. History (Tuskegee, Nazi experiments) is the record of tragedies committed under the banner of good intention.

The four principles of medical ethics are the articulation, under these three conditions, of who must be protected, from what, and how. We take them in turn from the next section.

02The four principles at a glance

Beauchamp and Childress reorganized the Belmont Report's three principles into the modern four in their Principles of Biomedical Ethics (1979). This is the framing that runs clinical ethics today.

The four are not standalone rules. In real settings they collide. "The patient wants to refuse treatment (autonomy). But refusing means death (beneficence)." Reading collisions like this is what the four principles are for.

03Autonomy — "the decider is the person"

Autonomy is the strongest of the four. It is the principle that has been reaffirmed, again and again, as the response to history. The Nazi experiments, Tuskegee, thalidomide — all are cases where the body was invaded without the person's agreement.

Autonomy plays out in three classic scenes:

• Choice of treatment direction — continue chemotherapy, or shift to palliative care. The patient chooses
• Trial participation — informed consent under an IRB-approved protocol; the procedural form mandated by the Declaration of Helsinki
• End-of-life decisions — ventilator, CPR, feeding tubes. Advance directives and living wills support the patient's voice

Autonomy has preconditions: that the person can decide, that they have enough information, and that no external coercion is bending them. If any of the three is missing, a signed consent form is, ethically, not consent. Tuskegee is the textbook case of "consent" with all three missing.

04Non-maleficence — "first, do no harm"

Non-maleficence is the oldest principle in medicine — 2,400 years from Hippocrates. "Primum non nocere".

It sounds simple. In practice it is not. Because every treatment contains some harm. Chemotherapy hits the tumor and the healthy cells. Surgery cuts. Drugs carry effect and side-effect together. "Zero harm" is impossible. The realistic interpretation: avoid unnecessary harm; choose the option where benefit outweighs harm.

Three tests for non-maleficence in practice:

• Foreseeability of harm — was the possible harm reasonably foreseen?
• Acceptability of harm — is the harm acceptable given the benefit?
• Minimization of harm — is there a less harmful path to the same goal?

For pharma, this connects directly to "don't hide, don't minimize" for adverse-event information. If promotion plays down side effects, the clinician's "foreseeability" is broken, and harm reaches the patient. The strict balance demands made in material review are non-maleficence in operation.

05Beneficence — "actively deliver benefit"

Beneficence is the "do" counterpart to non-maleficence's "don't". A positive duty to act in the patient's benefit.

If you stop at non-maleficence, "do nothing" becomes the safest choice. Medicine cannot run on that. Take the risk, treat. Use a drug with side effects. Cut the body in surgery, then heal. Beneficence is the duty to deliver benefit even when that means taking risk.

Beneficence and non-maleficence are often in tension. "This surgery raises the survival chance by 60% but carries a 20% chance of serious sequelae." What do you choose? The decider — between beneficence and non-maleficence — is autonomy (the patient's values). When the first two collide, the third resolves.

For pharma, beneficence shows up as "delivering treatment options to clinicians and patients, accurately". Narrow the information and you narrow the patient's benefit-window. Drug information must be accurate and sufficient.

06Justice — "fair distribution"

Justice is the most social of the four. It steps past the patient–clinician dyad and asks how the whole society allocates medical resources.

Concretely:

• Access to new drugs — who can receive expensive oncology drugs? What does the insurance cover?
• Transplant priority — organs are scarce. Who comes first?
• Resource allocation in a pandemic — when ICU beds run out, who is prioritized (a question argued in COVID-19)?
• Burden and benefit in trials — who carries the trial risk, who reaps the eventual drug benefit (the ethics of trialing in low-income countries and selling in rich ones)?

Justice often collides with market logic. "Only those who can pay get treated" is rational as a market but problematic as justice. Japan's universal health insurance, the drug-pricing system, patient-assistance programs — these are institutional designs that balance market and justice.

For pharma, justice touches R&D, pricing, and market access all at once. "Make a drug that works" is not enough. "Make it reach those who need it, at a price and through a mechanism that holds" — that is justice in operation.

07Informed consent — where the four converge

The scene where the four principles sharpest collide is informed consent. It is not merely the procedure of getting a signature on a form.

Proper informed consent has four elements.

A signature without any one of the four — even on a legally valid form — is not ethical consent. Tuskegee's "consent" was built on a disclosure that was a lie. The legal form and the ethical reality are different things.

08Patient, family, clinician — the triangle

The four principles assume a patient-clinician dyad, but actual clinical care is a triangle: the patient themselves, the family, and the clinician.

Each pair has its own tensions.

• Patient vs Family: the patient does not want aggressive treatment, but the family says "try harder". Whose will wins?
• Patient vs Clinician: the medically recommended treatment is being refused by the person. The balance of expert recommendation and the right to decide
• Family vs Clinician: the patient is unconscious; family and clinician must decide as surrogates. The negotiation of family preference and medical judgment

The default priority is patient > family. When the patient's will is clear, it overrides family preference. That follows from autonomy. In Japan, family voice often runs strong culturally, making this triangle harder to navigate than in some Western settings.

Advance directives, living wills, Advance Care Planning (ACP) — these instruments exist to document the patient's will while they can still articulate it, so that when family and clinician must decide as surrogates, the patient's voice is still in the room.

09Clinical judgment — resolving collisions between the four

How does the field actually decide when the four principles collide? There is no universal answer, but there is a frame.

Step 1: identify which principles are in tension. "Autonomy vs beneficence". "Non-maleficence vs justice". Name the structure.

Step 2: weigh how strongly each principle applies. When life is on the line, non-maleficence weighs heavily. When the person's values are central, autonomy weighs heavily.

Step 3: bring in a third perspective — an ethics committee, IRB, or simply more than one clinician. Points that one person misses, multiple eyes catch.

Step 4: record the process and the reasoning. Later it becomes the material from which the organization learns.

10Application in pharma

For people working in pharma, the four principles act as a mirror for the ethical standard of their own work.

• Autonomy: deliver drug information in a form that lets clinicians and patients decide autonomously. Exaggerated claims breach autonomy
• Non-maleficence: deliver adverse-event information unhidden, unminimized, accurate. Excessive promotion breaches non-maleficence
• Beneficence: deliver the beneficial treatment options widely enough to be heard. Bias in information narrows the benefit-window
• Justice: design the price and the access so the drug reaches who needs it. Pricing and access live inside justice

Pharma's daily work — trial design, publication, information to healthcare professionals, patient support, price negotiation — every piece of it corresponds to one of the four principles. "Which principle does this work touch?" reorganizes how the day looks.